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ABSTRACT (Max 150 words) 
The finding of TDP-43 as a major component of ubiquitinated protein inclusions in 
amyotrophic lateral sclerosis (ALS) has led to the identification of 30 mutations in the 
TARDBP gene, encoding TDP-43. All but one are in exon 6, which encodes the glycine-
rich domain. The aim of this study was to determine the frequency of TARDBP mutations 
in a large cohort of motor neurone disease (MND) patients from Northern England (42 
non-SOD1 FALS, 9 ALS-FTD, 474 SALS, 45 PMA cases). We identified 4 mutations, 2 of 
which were novel, in 2 familial (FALS) and 2 sporadic (SALS) cases, giving a frequency of 
TARDBP mutations in non-SOD1 FALS of 5% and SALS of 0.4%. Analysis of clinical data 
identified patients had typical ALS, with limb or bulbar onset, and showed considerable 
variation in age of onset and rapidity of disease course. However, all cases had an 
absence of clinically overt cognitive dysfunction.  
 
KEYWORDS: MND, ALS, TDP-43, TARDBP, mutation 
 
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is one of the most common adult-onset, 
neurodegenerative diseases, characterised by progressive cell death of motor neurones 
(MNs) in the motor cortex, brainstem and spinal cord. Whilst the majority of cases are 
sporadic (SALS), a familial component is present in 5-10% (FALS), and is usually 
associated with an autosomal dominant mode of inheritance. To date, the most common 
cause of FALS is mutation of the SOD1 gene, although this only accounts for 20% of 
FALS cases (1). Although other autosomal dominant loci have been identified (2), so far 
mutations in the two genes senataxin (SETX) and VAMP-associated protein B (VAPB) 
have not been found to be a common cause of ALS in large cohorts (3). In contrast, SOD1 
mutations have been found worldwide both in FALS and in apparent SALS cases (4).  
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Approximately 3 to 10% of patients with ALS also show signs of frontotemporal dementia 
(FTD), whilst detailed neuropsychological evaluation reveals up to 50% of ALS cases have 
evidence of cognitive impairment (5-8). Studies of cases with ALS + dementia + 
Parkinson’s disease have revealed mutations in the MAPT gene, encoding the microtubule 
associated protein tau. In addition, two loci on chromosome 9, 9p12-p21 (9, 10) and 9q21-
q22 (11), have been identified through genetic linkage studies to harbour genes 
responsible for ALS+FTD.  
 
Neuropathological examination of both ALS and FTD cases has shown the presence of 
neuronal cytoplasmic inclusions (NCIs), which stain positive for ubiquitin, but negative for 
tau and -synuclein. Neumann and colleagues demonstrated that a major protein 
component of these inclusions was TAR DNA binding protein (TDP-43) (12). TDP-43, a 
ubiquitously expressed nuclear protein, was originally identified as a protein that binds the 
transactive response (TAR) region of DNA of HIV-1 (13). In addition to acting as both a 
transcriptional repressor and an activator of exon skipping (14), it also reportedly plays a 
role as a scaffold protein for nuclear bodies, through interaction with survival motor neuron 
(SMN) protein (15). A further functional role for TDP-43 in motor neurones may be the 
stabilisation of neurofilament light (NFL) mRNA by direct binding of TDP-43 to the 3’ 
untranslated region (UTR) of NFL (16). 
 
Mackenzie and colleagues, investigating TDP-43 pathology in a cohort of 111 ALS cases, 
demonstrated that TDP-43 pathology was associated with SALS, FALS (without SOD1 
mutation) and ALS + FTD, but not with SOD1-related FALS (17). This was followed by 
several screening studies where mutations and linkage of ALS was not found associated 
with the TARDBP gene, which encodes the TDP-43 protein (18, 19). However, 
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Sreedharan and colleagues identified mutations in exon 6 of TARDBP in two familial and 
two sporadic cases (20). This was supported by further studies identifying mutations in 
exon 6 in both familial and sporadic disease (21-25). The aim of the present study was to 
determine the frequency of TARDBP mutations in our large cohort of MND patients from 
the North of England and to establish the clinical phenotype associated with these 
mutations.  
 
MATERIALS AND METHODS 
The Sheffield MND Blood DNA Bank contains DNA extracted from 37 FALS, 8 ALS-FTD, 
407 SALS and 34 progressive muscular atrophy (PMA) cases. Additional DNA samples 
were isolated from 5 non-SOD1 FALS, 1 ALS-FTD, 67 SALS and 11 PMA cases identified 
in the Sheffield Brain Tissue Bank, providing a cohort of 42 non-SOD1 FALS, 9 ALS-FTD, 
474 SALS and 45 PMA cases. ALS patients had definite or probable ALS as defined by 
the El Escorial criteria. Cases with SOD1 mutations were excluded from the analysis. DNA 
was extracted from blood using the Nucleon BACC Genomic Extraction kit (Tepnel, UK) 
according to the manufacturer’s protocol, whilst DNA was extracted from fresh frozen 
cerebellar samples using the Soft Tissue DNA Extraction Kit (Tepnel, UK). Control DNA 
(n=183) was extracted from blood donated by partners or unrelated carers of MND 
patients. Additional controls were obtained from the Birmingham MND DNA bank (n=316). 
All samples were from UK Caucasians. The South Sheffield Research Ethics Committee 
approved the study and informed consent has been obtained for all cases. 
 
The TARDBP gene comprises of 6 exons of which the first exon is non-coding(24). 
Primers were designed to amplify the 6 exons (Ensembl transcript ID: ENST00000240185) 
as well as the intron/exon boundaries (Table 1). PCR products were treated with ExoSAP-
IT (GE Healthcare) before bi-directional sequencing using BigDye Terminator v3.1 (ABI) 
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according to the manufacturer’s protocol. The resulting reactions were electrophoresed on 
a DNA Analyser 3730 capillary sequencer (ABI). The chromatographs were analysed by 
Sequencher (Gene Codes Corporation, USA) and any potential mutations validated by 
sequencing a second PCR reaction. 
 
To screen for the presence of the exon 6 nucleotide changes in the general population, 
499 neurologically normal age-matched Caucasian controls were bi-directionally 
sequenced as described above. Control DNA samples (n=183) were also bi-directionally 
sequenced to screen for the exon 3 nucleotide change.  
 
To establish the effect of the identified TARDBP mutations, quantitative PCR (QPCR) of 
CDK6 was performed on fibroblasts derived from patients carrying TARDBP mutations. 
RNA was extracted from 3 mutant TARDBP fibroblasts (p.G287S, p.A321V, p.M337V) and 
6 control fibroblast cultures using the RNeasy Mini Kit, according to manufacturer’s 
protocol (Qiagen). Following cDNA synthesis using Superscript II (Invitrogen), QPCR was 
used to determine the expression levels of CDK6 (Assay ID Hs01026372_m1, Applied 
Biosystems) in each of the samples. ACTB (Applied Biosystems) was used as the 
endogenous control. Reactions were run on an MX3000 (Stratagene) and data analysed 
using MX Pro. An unpaired T-test was used to establish if CDK6 expression levels were 
significantly different to controls.  
 
RESULTS 
Mutation screening of the 6 exons of the TARDBP gene, including intron/exon boundaries, 
in 42 FALS, 9 ALS-FTD, 474 SALS and 45 PMA cases identified 4 mutations in exon 6, of 
which 2 were novel. In addition, we identified 2 novel SNPs in the 5’UTR, 3 novel 
synonymous SNPs, 1 previously published synonymous SNP in the coding region and 3 
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intronic substitutions. A further non-synonymous change was found in a patient and a 
control (Table 2). 
 
The 4 TARDBP mutations were found in 2 FALS cases and 2 SALS cases. In the first 
family (FALS1), the index case showed a c.1009A>G substitution leading to p.Met377Val 
(Fig 1a). Screening of family members showed that the sister of the index case, who is 
also affected with ALS, carries the mutation, whilst an unaffected brother was homozygous 
for the wild type allele (Fig 1b). In the second family (FALS2), a c.1043G>T substitution 
was found in the index case, leading to a p.Gly348Val amino acid change (Fig 2a). 
Screening of a brother, who was also affected with the disease, showed he also carried 
the mutation (Fig 2b). The two mutations found in SALS cases were a c.859G>A 
substitution which results in a p.Gly287Ser amino acid alteration (SALS1) and a c.962C>T, 
which leads to a p.Ala321Val substitution (SALS2) (Fig 3). None of these four mutations 
were found in 499 neurologically normal controls.  
 
In addition, in a third SALS case (SALS3) an exon 3 c.269C>T substitution was identified, 
which encodes the amino acid alteration p.Ala90Val. Screening of controls also identified 
this mutation in a male aged 78 years at time of donation. Since it has also been published 
previously in controls, this substitution is likely to represent a non-pathogenic 
polymorphism (18, 20, 21).  Novel synonymous SNPs were identified in 3 SALS cases in 
exon 2 (p.Leu27), exon 3 (p.Ser104) and exon 4 (p.Lys137), along with two SALS cases 
carrying the previously reported p.Ala66 SNP in exon 2 (18, 21, 23, 26-28).  
 
Functional implications of the mutations: 
The five amino acid substitutions were run through several databases to predict the effects 
of the alteration on the structure and function of the protein (Table 3). The two FALS 
 7 
 
mutations p.M337V and p.G348V and the novel SALS mutation p.A321V are all predicted 
to be pathological according to PMut, and the two FALS mutation are also likely to be 
damaging, according to PolyPhen. In contrast, the G287S substitution found in SALS1 is 
listed as benign by PolyPhen and neutral by PMut, as is the A90V variant, found in both a 
case and control.  
 
In order to establish the functional implications of the TARDBP mutations in-vivo, we 
obtained fibroblast cultures from 3 ALS patients, carrying the p.G287S, p.A321V and 
p.M337V. TDP43 has been shown to repress the expression of cyclin-dependent kinase 6 
(CDK6), via GT repeats in the CDK6 sequence (29). QPCR showed that CDK6 transcript 
levels were increased in the mutant TARDBP fibroblast samples, compared to levels in 
controls (Fig 4), suggesting that the three mutant TDP43 proteins were unable to repress 
CDK6. 
 
Clinical phenotypes: 
These are summarised in Table 4. 
FALS1: (Fig 1) 
The index case (II.1) developed mild dysarthria at the age of 57 years. Subsequently he 
went on to develop a mild distal weakness with loss of dexterity in the left hand and 
painless left foot drop. The signs were of a classical ALS phenotype with mixed upper and 
lower motor signs in the bulbar and limb regions. Disease progression has been slow and 
48 months since the onset of symptoms the individual remains ambulant with assistance, 
manages an oral diet with consistency changes, and is free from respiratory symptoms. 
The ALS functional rating scale (ALSFRS) score at his last visit was 32/40. Forced vital 
capacity (FVC) measurements are unreliable due to his bulbar disease but daytime pCO2 
measurements are normal. 
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A sister (II.2) at 42 years old, developed progressive weakness of the right hand. Within 
three years the individual had similar problems in the left arm and had developed a spastic 
dysarthria and mild dysphagia. Seven years into the illness the lower limbs were affected 
with slow walking only possible over short distances. Nine years after onset of symptoms 
the individual was effectively wheel chair bound and had begun to develop symptoms of 
respiratory insufficiency. Over the next decade the disease slowly progressed and the 
individual died of pneumonia, 17 years after disease onset. 
A brother (II.4) developed ALS at the age of 31 and experienced rapid disease 
progression, dying only 9 months after the onset of symptoms. The daughter of II.4, III.1, 
has a progressive neurodegenerative disorder affecting the pyramidal and cerebellar 
systems. III.1 was born by Ventouse extraction at term after a normal pregnancy and 
initially achieved normal milestones, walking by 11 months. However by the age of 2.5 
years language and intellectual impairment was apparent. Her walking deteriorated over a 
decade until she was largely confined to a wheelchair. In addition, at the age of 12 years 
she developed generalised seizures. The major features on examination were a spastic 
tetraparesis with relatively preserved power, a concomitant convergent strabismus, and 
intellectual impairment. Investigations revealed an atrophic cerebellum on MRI scan, with 
other investigations normal, including nerve conduction studies, electro-myography (EMG), 
lysosomal enzymes, genetic screening of SCA 1-3, SCA 6, SCA7, Frataxin and DRPLA.  
The mother (I.2) of the index case, developed progressive loss of voice and limb 
weakness due to MND at the age of 55 and died of the illness 6 years later. A further 
brother (II.3), who does not carry the p.M337V mutation is healthy at the age of 51, with no 
evidence of ALS.    
 
FALS2:  (Fig 2) 
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The index case (II.1) developed painless left foot drop when 51 years old. Weakness 
progressed to the left leg and right arm before becoming generalised involving respiratory 
muscles. Bulbar function remained relatively intact throughout the disease course. Signs of 
upper motor neurone involvement were subtle and consisted of retained reflexes in the 
context of muscle wasting. Respiratory dysfunction necessitated non-invasive ventilation. 
The individual died from respiratory failure, 36 months from symptom onset. 
The younger brother (II.2) developed progressive weakness of the right upper limb at 57 
years of age. The weakness progressed bilaterally resembling a flail arm phenotype of 
MND, before becoming generalised affecting all limbs and respiratory muscles. Upper 
motor neurone involvement and bulbar dysfunction were again minimal. Thirty-six months 
after symptom onset the individual died from respiratory failure.  
In the preceding generation, the mother (I.2) had died from MND at the age of 65 years. A 
maternal aunt (1.3) and uncle (1.4) were reported to have died from muscular atrophy in 
their 40’s. No further information was available on these cases. 
 
SALS1: This individual presented at the age of 52 years with a 2-year progressive history 
of clumsiness of the left hand and left leg.  At presentation the individual had mixed upper 
and lower signs in the left upper and lower limbs with dysarthria and a weak fasciculating 
tongue. The disease in this individual has run a relatively indolent course and 6 years 
following symptom onset bulbar symptoms remain mild and there is no evidence of 
respiratory insufficiency. Limb weakness has progressed with some help required with 
activities of daily living such as dressing and a wheelchair is necessary for travelling 
outside the home. There is no known family history of neurological disease. 
 
SALS2: This individual developed progressive weakness and loss of dexterity of the left 
hand at the age of 38 years. On examination there were mixed upper and lower motor 
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neurone signs in the left upper limb. EMG demonstrated more widespread denervation 
consistent with a diagnosis of ALS and investigation, including imaging of the neuroaxis, 
has not identified an alternative cause. The individual, two years following the onset of 
symptoms, is experiencing increasing weakness of the left hand and fatigue but no other 
major problems, particularly no dysarthria, dysphagia or leg weakness.  There is no family 
history of neuromuscular disorder. Her mother died at the age of 44 years and father at 62 
years both due to malignancy. Two siblings are healthy at the ages of 37 and 41 years.   
 
It should be noted that the mutations were all found in DNA from the Sheffield MND Blood 
DNA Bank, rather than the Sheffield Brain Tissue Bank. Therefore no neuropathological 
investigation has been possible in these cases. 
 
DISCUSSION 
Screening of a large cohort of MND cases including 42 FALS and 474 SALS has identified 
4 mutations in exon 6 of the TARDBP gene, the p.Gly287Ser and p.Ala321Val in two 
SALS cases and the p.Met337Val and p.Gly348Val in two FALS cases. This suggests a 
frequency for TARDBP mutations in Northern England of 5% for FALS and 0.4% for SALS. 
Three novel synonymous substitutions were also identified in cases of SALS, p.Leu27, 
p.Ser104 and p.Lys137. An additional non-synonymous substitution p.Ala90Val, which has 
previously been found in controls (20, 21), was also found in a SALS case. Although it is 
predicted to have no effect on protein function, in-vitro studies have shown mis-localisation 
of this protein (30).  
 
Broad clinical ALS phenotypes are associated with TARDBP mutations: 
The clinical phenotype encompasses patients with bulbar, limb and respiratory onset 
disease, and with short and long disease durations. All our patients had clinical features in 
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keeping with ALS and no mutations were found in patients with a pure lower MN clinical 
phenotype (PMA). It is noteworthy that despite TDP-43 protein inclusions being originally 
identified in FTD cases, none of the FALS or SALS cases published to date show any 
evidence of overt dementia.  However, two mutations in TARDBP, p.K263E and 
c.2076G>A in the 3’UTR, have recently been found to be associated with individuals 
diagnosed with FTD (31, 32). Further post-mortem studies in cases with TARDBP 
mutations may elucidate differential pathologies in these cases compared to the range of 
TDP-proteinopathies that show TDP-43 inclusions.  
 
The familial p.Met337Val mutation has been identified in three other families with MND 
(20, 23, 28). In FALS1 (Met337Val) a marked intrafamilial variation in disease duration was 
observed, ranging from 9 months to 17 years. The average disease duration was 6.9 years 
compared to 5.5 years in the published detailed pedigree. Age at onset of symptoms is 
consistent with that previously published as is the classical ALS/MND phenotype 
observed. It is unclear whether the atypical phenotype manifesting in individual III.1 from 
this family is as a result of expression of TDP-43 mutation, as genetic testing has not been 
possible. 
 
The familial p.Gly348Val mutation is a novel substitution, though p.Gly348Cys has been 
reported in four SALS cases from France, two cases in a family from Germany and in a 
large multigenerational family from Belgium (21, 22, 26, 27). In FALS2 the phenotype 
observed was predominantly lower motor neurone, with only subtle upper motor neurone 
changes consisting of retained reflexes in the context of wasting. In individual II.2 the 
disease initially resembled the flail arm variant. Bulbar function also remained intact in 
these individuals. In a previously reported mutation affecting this amino acid it was also 
commented that there was a lack of bulbar symptoms (22). A paucity of upper motor 
 12 
 
neurone signs has been described with other mutations (21). The age at onset and 
duration were comparable with other published pedigrees.  
 
The p.Gly287Ser mutation has been described previously in 2 SALS cases, one from 
France, the other from Italy (21, 28). In our SALS1 case, the age of onset was 52 years, 
beginning in the limb. Whilst the Italian case also had spinal onset, at the age of 70 years, 
the French case presented with bulbar onset at 65 years. In all three cases disease course 
has been relatively indolent with the affected individuals still living 5-7 years after symptom 
onset.  
 
Therefore, taking into account all the published reports of ALS cases with TARDBP 
mutations, there does not appear to be any correlation between the age of onset, site of 
onset and disease duration of the patients with specific TARDBP mutations, taken either 
individually or as a group.  This is a similar scenario to that observed in SOD1-related 
MND, where there is both inter and intra-familial variation with the same mutation. Also in 
line with SOD1, mutations in TARDBP are found in both familial and sporadic forms of the 
disease, with frequencies of TARDBP mutations from 0.6 to 6.5% for FALS and 0 to 5% 
for SALS, depending on the population sampled (20-26, 28, 33). This compares with 
SOD1 mutation frequencies of 12-24% for FALS and 0-7% for SALS (4).  
 
Functional effects: 
All but one of the mutations identified to date reside in exon 6 of the TARDBP gene, which 
encodes for the end of the second RNA recognition motif (up to amino acid 262) and the 
entire glycine-rich domain of the TDP-43 protein (aa 274-413) (Swiss-Prot Q13148 
TARDBP_HUMAN). This C-terminal region of the protein shows high levels of 
conservation (Fig 5) and the 4 mutations all affect highly conserved amino acid residues, 
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which show conservation in mammals as well as chicken and zebrafish.  The glycine-rich 
domain is involved in regulating alternative splicing, as demonstrated with cystic fibrosis 
transmembrane conductance regulator (CFTR) and apolipoprotein A-II (APOA2). This 
domain has also been shown to bind several hnRNP proteins involved in mRNA synthesis 
(14, 34, 35). The C-terminal of TDP-43 has also been implicated as a transcriptional 
repressor. Thus mutations in this region could have several deleterious effects on the 
function of the protein. Sreedharan has demonstrated that expression of the mutant 
p.M337V TDP-43 in the chick embryo results in the failure of normal limb and tail bud 
development (20). In addition, both Kabashi and Rutherford show increased aggregation 
of detergent insoluble mutant TDP-43 (21, 23). 
 
Our bioinformatic analyses suggest that the two FALS and the novel SALS mutation are 
predicted to alter the function of the protein, whilst the p.Gly287Ser mutation, which has 
been found in an additional SALS case, is not predicted to have a major effect on the 
protein. However, QPCR of CDK6, which is repressed by TDP-43, shows an increase in 
expression in fibroblasts carrying the mutant proteins p.G287S, p.A321V and p.M337V. 
Therefore, we propose that these 3 mutants are unable to repress CDK6 as efficiently as 
the control fibroblasts.   
 
In conclusion, mutations in TARDBP are found at a frequency of 5% for non-SOD1 FALS 
and 0.4% for SALS in a large cohort of MND cases from Northern England. As found 
previously, these mutations reside in exon 6 of the gene, potentially interfering with the 
function of the glycine rich domain. Analysis of clinical data suggests variability in the 
disease phenotype, though it is of note that the MND cases show no overt dementia 
symptoms.  
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FIGURE LEGENDS 
 
Fig 1 a) Chromatograph showing the c.1009A>G nucleotide substitution identified in 
FALS1 and other affected members of the family. b) Pedigree of FALS1 family. The index 
case is indicated by a *. WT = wild type, homozygous for M337 
 
Fig 2 a) Chromatograph showing the c.1043G>T nucleotide substitution identified in 
FALS2 and the other affected family member. b) Pedigree of FALS2 family. The index 
case is indicated by a * 
 
Fig 3 Chromatograph showing the a) c.859G>A nucleotide change in SALS1 and b) 
c.962C>T in SALS2 
 
Fig 4 Expression levels of CDK6, relative to ACTB, in mutant TARDBP and control 
fibroblast cultures. * p=0.015. 
 
Fig 5 Alignment of the TDP-43 protein sequence encoded by exon 6 in human. Protein 
sequences used in the alignment are Human (Q13148), Chimpanzee (Pan 
troglodytes:XP_001135199), Orangutan ( Pongo abelii:Q5R5W2), Mouse (Mus 
musculus:Q921F2), Chicken (Gallus gallus:Q5ZLN5), Xenopus (X.tropicalis:Q28F51) and 
zebrafish (Danio rerio: Q802C7). Location of the mutations identified in Sheffield MND 
cases are highlighted in green (p.G287S, p.A321V, p.M377V, p.G348V). The locations of 
the other published mutations in exon 6 are highlighted in blue (p.G290A, p.N267S, 
p.G294A/V, p.G295S/R, p.G298S, p.M311V, p.A315T, p.Q331K, p.S332N, p.G335D, 
p.Q343R, p.N345K, p.N352S, p.R361S, p.P363A, p.Y374X, p.S379P/C, p.A383T/P, 
p.I383V, p.N390S/D and p.S393L) p.G348C has also been reported. 
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Table 1: PCR primers used to amplify the TARDBP gene. Primer sequences, annealing 
temperature and size of product are given. All PCR reactions were carried out using the 
following programme: Initial denaturation of 95oC for 5 mins, followed by 35 cycles of 95oC 
for 30 secs, specific annealing temperature for 30 secs, and 72 oC for 45 secs, followed by 
a final elongation step of 72 oC for 10 mins to complete the programme. 
 
Primer  Sequence Annealing 
Temperature 
Product  
Size 
TARDBP.1F 
TARDBP.1R 
ggc agc ccg agt ccc tgg gga gag g 
ctc ggg ccg ccc caa tgc aga aag 
61oC 277bp 
TARDBP.2F 
TARDBP.2R 
tgg ttt ggg tat tat cat t 
cca cca aaa gag gct aag a 
49 oC 411bp 
TARDBP.3F 
TARDBP.3R 
tag atg tag gag gta gtg ttt tta 
ata cca ataaat aaa tgc ta 
50 oC 330bp 
TARDBP.4F 
TARDBP.4R 
taa gtt taa gcc act gca tcc ag 
ggc caa aga ctt caa caa gac aa 
54 oC 400bp 
TARDBP.5F 
TARDBP.5R 
aag gcg aat gat ttt gtt 
aaa gtg ctg gga ttg taa g 
51 oC 332bp 
TARDBP.6F 
TARDBP.6R 
tat atg aat cag tgg ttt aat ctt 
caa tat act tac cat gag ttt aga 
50 oC 656bp 
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Table 2: TARDBP nucleotide substitutions identified in FALS and SALS cases. All 
mutations reported according to the Human Genome Variation Society guidelines. 
Numbering is taken from the Ensembl transcript ID ENST00000240185. * The ATG 
resides in exon 2, therefore the first nucleotide of exon 2 is called c.-12. 
 
SAMPLE 
 
EXON DNA PROTEIN  COMMENTS 
SALS1 
 
6 
 
c.859G>A p.Gly287Ser 
 
Previously seen in SALS 
(21, 28) 
SALS2 
 
6 c.962C>T p.Ala321Val Novel mutation 
FALS1 
 
6 c.1009A>G p.Met337Val Previously seen in FALS 
(20, 23, 28) 
FALS2 
 
6 c.1043G>T p.Gly348Val Novel mutation 
(p.Gly348Cys previously 
reported) (21, 22, 26, 27) 
SALS3 and 
CONTROL1 
3 c.269C>T p.Ala90Val Previously reported in 
control samples (18, 20, 
21) 
SALS4 1 c.-69C>T 5’UTR Novel polymorphism 
 
SALS5 1 c.-66G>T 5’UTR Novel polymorphism 
 
SALS6 
 
Intron 1 c.-12-54G>A*  Novel polymorphism 
FALS3 
 
2 c.81G>A p.Leu27 Novel polymorphism, 
synonymous change 
SALS7 and 
SALS8 
2 c.198T>C p.Ala66 rs61730366, synonymous 
change (18, 21, 23, 26, 27) 
SALS9 
 
3 c.312C>T p.Ser104 Novel polymorphism 
synonymous change 
SALS10 
 
4 c.411A>G p.Lys137 Novel polymorphism, 
synonymous change 
SALS11 Intron 3 
 
c.403-80G>A  Novel polymorphism 
SALS12 Intron 4 
 
c.543+112C>A  Novel polymorphism 
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Table 3: Summary of bioinformatic analyses to determine the functional effects of the non-
synonymous changes identified in our samples. G348C is also included for comparison.  
 
Mutation 
 
I-Mutant NetPhos PolyPhen PMut 
A90V 
 
Decreased 
stability 
No change Benign 
substitution 
Neutral 
 
G287S 
 
Increased 
stability 
Serine not 
phosphorylated 
Benign 
substitution 
Neutral 
A321V 
 
Decreased 
stability 
No change Benign Pathological 
M337V 
 
Decreased 
stability 
No change Possibly 
damaging 
Pathological 
 
G348V 
 
Increased 
stability 
No change Probably 
damaging 
Pathological 
G348C 
 
Increased 
stability 
No change Probably 
damaging 
Pathological 
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Table 4: Summary of clinical details for the TARDBP-related ALS cases. n/a = not 
applicable, * = index case, a = individual alive at time of writing. WT = wild type, 
homozygous for M337 
 
 MND 
Status 
Mutation Age of 
Onset 
Site of Onset Duration Dementia 
FALS1       
I:2 Affected Not tested 55 Cervical/Bulbar 6 yrs  
II:1* Affected M337V 57 Bulbar >4 yrsa No 
II:2 Affected M337V 42 Cervical 17 yrs No 
II:3 Unaffected WT n/a n/a n/a n/a 
II:4 Affected Not tested 32 Cervical 9 mths  
III:1 Unclear Not tested 2.5 n/a >15 yrsa Intellectual 
impairment 
       
FALS2       
I:2 Affected Not tested Unknown Unknown Died at 
65yrs 
Unknown 
II:1* Affected G348V 57 Lumbar 3 yrs No 
II:2 Affected G348V 52 Cervical 1yr 9 mths No 
       
SALS1 Affected Gly287Ser 52 Cervical/Lumbar >6 yrsa No 
SALS2 Affected Ala321Val 38 Cervical >2 yrsa No 
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Fig 2 
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Fig 3 
 
a)                                                                      b) 
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Fig 5 
 
 
Human              IAQSLCGEDLIIKGISVHISNAEPKHN-SNRQLERSGRFGGNPGGFGNQGGFGNSRGGGA 
Chimpanzee         IAQSLCGEDLIIKGISVHISNAEPKHN-SNRQLERSGRFGGNPGGFGNQGGFGNSRGGGA 
Orangutan          IAQSLCGEDLIIKGISVHISNAEPKHN-SNRQLERSGRFGGNPGGFGNQGGFGNSRGGGA 
Mouse              VAQSLCGEDLIIKGISVHISNAEPKHN-SNRQLERSGRFGGNPGGFGNQGGFGNSRGGGA 
G.gallus           VAQSLCGEDLIIKGISVHISNAEPKHN-SNRQLERGGRFGGNPGGFGNQGGFGNSRGGGG 
X.tropicalis       VAQSLCGEDLIIKGVSVHVSTAEPKHN-NNRQLERGGRFPGP--SFGNQG-YPNSRPSSG 
D.renio            VAAALCGEDLIIKGVSVHISNAEPKHNNTRQMMERAGRFGNGFGGQGFAGSRSNMGGGGG 
                    
 
 
Human              GLGNNQGSNMGGG--MNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQN 
Chimpanzee         GLGNNQGSNMGGG--MNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQN 
Orangutan          GLGNNQGSNMGGG--MNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQN 
Mouse              GLGNNQGGNMGGG--MNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQS 
G.gallus           GLGNNQGSNMGGG--MNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQP 
X.tropicalis       ALGNNQGGNMGGGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPQGSNQG 
D.renio            GSSSSLG---------NFGNFNLNPAMMAAAQAALQSSWGMMGMLA-QQNQSGTSGTSTS 
                    
 
Human              QGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSG-SGFNGGFGSSMDSKSSGWGM 
Chimpanzee         QGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSG-SGFNGGFGSSMDSKSSGWGM 
Orangutan          QGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSG-SGFNGGFGSSMDSKSSGWGM 
Mouse              QGSMQREPNQAFGSGNNSYSGSNSGAPLGWGSASNAGSG-SGFNGGFGSSMDSKSSGWGM 
G.gallus           QGNMQREQNQGFSSGNNSYGGSNSGAAIGWGSASNAGSS-SGFNGGFGSSMDSKSSGWGM 
X.tropicalis       QGNQQRDQPQSFGSNNSYGSNSG---AIGWGSP-NAGSG-SGFNGGFSSSMESKSSGWGM 
D.renio            GTSSSRDQAQTYSSANSNYGSSS--AALGWGTGSNSGAASAGFNSSFGSSMESKSSGWGM 
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